Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | CASR | P41180 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3669166 | 0.75 | POLB (0.42) | POLBCYP4A11CYP4F2KDM4EGLA | |
| SCHEMBL3673643 | 0.71 | ABL1 (0.42) | POLBCYP4A11CYP4F2KDM4EGLA | |
| SCHEMBL3664402 | 0.68 | KMT2A (0.38) | POLBKDM4EGLANR4A2 | |
| SCHEMBL3667824 | 0.68 | ALDH1A1 (0.41) | POLBKDM4EGLA | |
| SCHEMBL3671045 | 0.67 | P2RX7 (0.36) | POLBKDM4EPTGS2NR4A2P2RX7 | |
| SCHEMBL3674113 | 0.67 | ALDH1A1 (0.37) | POLBKDM4E | |
| SCHEMBL3675414 | 0.66 | NPC1 (0.34) | POLBKDM4EGLAPTGS2P2RX7 | |
| SCHEMBL3670184 | 0.66 | KDM4E (0.49) | KDM4EGLAPTGS2 | |
| SCHEMBL4090979 | 0.65 | ALDH1A1 (0.35) | POLBKDM4EGLANR4A2P2RX7 | |
| SCHEMBL3672205 | 0.65 | ALDH1A1 (0.38) | POLBKDM4EGLAPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785460-B2 | Tricyclic compounds and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-07-22 | — | — | US | disclosed |
| US-20090186879-A1 | TRICYCLIC COMPOUNDS AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186879-A1 | TRICYCLIC COMPOUNDS AND USE THEREOF | CRHR1, CRHR2, HCRTR1 | POLB 4669/4885CYP4A11 220/4885CYP4F2 546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.